Articles
Tesla's Full Self-Driving System Faces Hardware Challenges in Sunlight Conditions
Investor Ross Gerber Highlights Limitations of Tesla's FSD Under Direct Sun Exposure
Investor Ross Gerber has raised concerns about Tesla Inc.'s full self-driving (FSD) technology, emphasizing difficulties the system encounters when dr...
Injury to Canadian Pair Skater Stellato-Dudek Challenges Olympic Figure Skating Prospects
Canada's figure skating team faces adjustments after Deanna Stellato-Dudek's pre-competition injury at Milan Cortina Games
Deanna Stellato-Dudek and Maxime Deschamps, Canada's top pair skating duo and former world champions, have withdrawn from the Olympic team figure skat...
Sistine Chapel's Iconic 'The Last Judgment' Embarks on Extensive Cleaning Project
Vatican Initiates Three-Month Restoration of Michelangelo’s Fresco Amidst Continuous Visitor Flow
Michelangelo’s renowned fresco 'The Last Judgment' located in the Sistine Chapel is currently undergoing its first significant cleaning in 30 years....
Federal Judge Enables Resumption of Troubled Offshore Wind Project Serving New York
Sunrise Wind project cleared to continue construction, marking the fifth such development to restart after prior administration's halt
A federal court has permitted the Sunrise Wind offshore project off New York to resume construction, reversing a suspension imposed by the previous ad...
Twist Bioscience Reports Q1 2026 Results, Boosts Fiscal Year Revenue Forecast
Company posts solid sales growth, narrows EBITDA losses, and anticipates profitability by year-end while expanding customer base and product shipments
Twist Bioscience Corporation delivered a strong performance in its first quarter of fiscal 2026, showing year-over-year sales growth of 17%, a reduced...
Oracle Plans $50 Billion Capital Raise to Boost Cloud Infrastructure
Oracle announces significant multi-billion dollar fundraising initiative amid investor concerns over rising debt and legal challenges
Oracle Corporation has unveiled plans to secure between $45 billion and $50 billion in 2026 to support expansion of its cloud infrastructure. The mixe...
Avalo Therapeutics Navigates Phase 2 Milestone with Potential for Significant Stock Gains
Upcoming Phase 2 LOTUS Trial Results Could Drive Avalo Stock Price More Than 200% Higher Pending Efficacy Readouts
Avalo Therapeutics has completed enrollment in its pivotal Phase 2 LOTUS trial evaluating AVTX-009 in moderate to severe hidradenitis suppurativa pati...
DRS: Take-Profit Time — Why I'm Trimming a Winner After the Run
Strong-buy call worked. The macro tailwind stays, but valuation and near-term technicals say reduce and rotate to the sidelines.
Leonardo DRS executed: consecutive quarters of revenue and earnings growth plus dividends supported a sizable run in the stock. With shares trading ne...
Buy the Cash Machine, Ignore the Chatter - Uber Q4 Play
Strong cash flow and durable operating profits create a tactical long setup ahead of Q4 results — trade the reaction, not the headlines.
Uber is consistently printing operating cash (roughly $2.3B+ per quarter) and turned operating profits in recent quarters, but investors are focused o...
Alaska Air Group - A Year in Review and a Tactical Long Setup
Q3 2025 showed progress but cash flow erosion and leverage still matter — a tactical swing trade with defined risk.
Over the past year Alaska Air Group (ALK) moved from deep cyclical volatility to modest operating profitability. Recent quarters show a recovery in re...
Apple Beats the Doubters Again: Buy on Strength with Defined Risk
Record Q1 results, robust cash generation, and steady dividends justify a Buy. Enter near $267 with tight risk controls.
Apple's 01/29/2026 quarter surprised on both revenue and EPS, reinforcing the company's cash-generation engine and giving investors a low-friction opp...
Wave Life Sciences Reacquires Rights to WVE-006, Boosts Clinical Development Plans
Company regains full control of rare disease therapy candidate, advances regulatory strategy and collaboration with GSK
Wave Life Sciences announced it has regained exclusive rights to WVE-006 from GSK, positioning the company to accelerate development in alpha-1 antitr...